Pre-launch price forecasting for rare disease assets was tested against two named products in 2024. GPI Horizon predicted the annual cost of treatment for mirdametinib (NF1-associated plexiform neurofibromas) and nirogacestat (desmoid tumours) across the EU4, UK, and Japan. When both products launched, the observed 2025 prices sat close to or within the predicted ranges. This article documents the methodology, the case-specific challenges each asset presented, and what the outcomes suggest about structured pre-launch pricing analysis in rare disease indications with small analogue sets.
Two rare disease assets, two pre-launch forecasts – and what the 2025 prices actually showed
For pricing and market access teams, pre-launch price forecasting is often one of the most difficult decisions to make. With limited market evidence, evolving competitive landscapes, and uncertainty around payer perceptions, forecasts can quickly become dependent on assumptions rather than evidence.
But what if there was a way to establish an evidence-based pricing expectation before a product reaches the market?
This is precisely the challenge GPI Horizon was designed to address.
GPI Horizon provides a structured, evidence-based approach to pre-launch asset valuation. The platform uses a multi-criteria decision analysis (MCDA) framework to assess an asset across a range of clinical and product attributes, using payer-validated value frameworks derived from HTA evidence. Relevant analogue products are assessed using the same framework, creating a standardised basis for comparison.
The resulting value scores are analysed alongside the annual cost of treatment (COT) of analogue products. By evaluating the relationship between asset value and annual COT through regression analysis, Horizon translates a product’s assessed value into an evidence-based estimate of expected annual treatment cost.
This creates more than a price estimate. It provides a story behind the number: the predicted COT is linked to the product’s assessed value and its position relative to relevant analogues, allowing different assumptions around value and competitive positioning to be explored through scenarios or price corridors.
Testing Horizon’s Pre-Launch Predictions: Two Case Studies
How does structured pre-launch price forecasting work for rare disease assets?
In 2024, Horizon was used to estimate the pricing potential of two rare disease assets prior to launch:
The question was simple: once these products launched, how closely would Horizon’s predictions align with reality?
Mirdametinib: Treatment for NF1-associated plexiform neurofibromas
How did GPI Horizon forecast the price of mirdametinib before launch?
Challenge: A key consideration affecting price was the product’s second-to-market positioning, balanced by its broader indication covering both adult and paediatric patients and a more favourable safety profile compared with selumetinib. Other MEK inhibitors were also understood to have been used off-label when selumetinib was not tolerated.
Nirogacestat: Treatment for desmoid tumours
How did GPI Horizon forecast the price of nirogacestat under comparator uncertainty?
Challenge: A key uncertainty was whether off-label therapies used in desmoid tumours would be considered relevant comparators for pricing and reimbursement evaluations.
What GPI did:
GPI combined its proprietary pricing and reimbursement platform, GPI Horizon, with consulting expertise to assess the pricing and reimbursement landscape across the EU4 (France, Germany, Italy, and Spain), UK, and Japan for both assets.
- For Mirdametinib: Conducted scenario analyses to evaluate the impact of market-entry timing, clinical value, and competitive positioning on potential pricing outcomes.
- For Nirogacestat: Conducted scenario analyses to assess pricing implications under different standards of care, including scenarios where tyrosine kinase inhibitors (TKIs) were considered relevant comparators.
Relevant analogue products were selected based on disease burden, survival duration, patient population size, regulatory status, and availability of HTA assessments. This ensured robust benchmarking against assets with comparable value drivers and market characteristics.
Horizon predicted annual COT for:
Mirdametinib

*Mirdametinib is approved in both adult and paediatric patients, but GPI used Horizon to predict COT for the adult population.
The observed 2025 annual COT was approximately 3% above the upper end of Horizon’s predicted range, indicating close alignment between the pre-launch estimate and the post-launch outcome.
Nirogacestat

The observed 2025 annual COT for nirogacestat fell within Horizon’s predicted COT range, demonstrating how scenario-based analysis can help account for uncertainty in pre-launch pricing assessment.

See how GPI Horizon forecasts pricing for your pre-launch asset.
Horizon applies the MCDA methodology used in the mirdametinib and nirogacestat cases to your asset, using payer-validated value frameworks, structured analogue selection, and regression analysis to translate assessed value into an evidence-based cost of treatment estimate.
Why this matters for pricing teams
What do these results mean for pharmaceutical pricing teams?
These cases demonstrate that pre-launch pricing does not need to rely solely on expert judgement or unstructured analogue benchmarking.
By connecting product value with real-world pricing patterns, Horizon provides pricing teams with a structured and evidence-based starting point for:
- Early price forecasting
- Internal business planning
- Scenario testing
- Launch preparation
- Payer engagement strategy
While no model can perfectly predict future prices, these examples show how robust value-based analytics can help reduce uncertainty long before launch. Both cases are rare disease assets with small, HTA-visible analogue sets, and validation in crowded indications with larger comparator pools remains an area of ongoing work.
| Set an early COT expectation | Explore uncertainty | Anchor pricing in evidence |
| Create a structured starting point for pricing discussions before launch. | Test alternative value and competitive-position assumptions through scenarios or price corridors. | Connect expected COT to observed relationships between product value and annual COT. |
Together, these cases demonstrate the potential of an evidence-based approach to bring greater structure and confidence to pre-launch pricing decisions.
By connecting assessed product value with observed pricing patterns, Horizon can help teams establish an early COT expectation, test uncertainty, and understand the assumptions driving potential pricing outcomes before launch.
FAQs
A: Accuracy depends on the methodology used and the quality of analogue selection. GPI Horizon predicted pre-launch pricing for two rare disease assets in 2024. For mirdametinib (NF1-associated plexiform neurofibromas), the observed 2025 annual cost of treatment came in approximately 3% above the upper end of the predicted range. For nirogacestat (desmoid tumours), the observed 2025 annual cost of treatment fell within the predicted range. Both cases involved small, HTA-visible analogue sets, and validation in crowded indications with larger comparator pools is ongoing.
A: Multi-criteria decision analysis (MCDA) is a structured framework that assesses a pharmaceutical asset across a range of clinical and product attributes using payer-validated value frameworks derived from health technology assessment (HTA) evidence. Relevant analogue products are assessed using the same framework, creating a standardised basis for comparison. In GPI Horizon, the resulting value scores are analysed alongside the annual cost of treatment of analogue products through regression analysis, translating an asset’s assessed value into an evidence-based estimate of expected annual treatment cost.
A: In GPI Horizon, relevant analogue products are selected based on disease burden, survival duration, patient population size, regulatory status, and availability of HTA assessments. This ensures benchmarking against assets with comparable value drivers and market characteristics. Analogue selection matters most in rare disease indications, where direct comparators may be limited or off-label therapies may need to be considered as reference points. In the nirogacestat case, scenario analyses were used to assess pricing implications under different standards of care, including scenarios where tyrosine kinase inhibitors were considered relevant comparators.

Working on a pre-launch pricing case for a rare disease asset?
GPI helps pharmaceutical teams build structured pre-launch pricing cases across the EU4, UK, US, and Japan using the Horizon framework. Whether you are preparing for board sign-off, testing scenarios against different standards of care, or planning payer engagement, we can help you anchor the pricing conversation in evidence.

